Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy? Terns Pharmaceuticals focuses on developing weight loss and oncology medicines.

The diabetes and weight ... loss drug Zepbound leading the way. Wells Fargo analyst Mohit Bansal kept a "buy" rating on LLY in a new research note with a price target of $1,100. The stock closed ...

Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price target on Wall Street implies significant upside potential. The drugmaker's ...

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss ... cap drugmaker's stock, $19.06 ...